Trial Profile
A 12-Month Noninterventional, Postmarketing, Multicenter Study to Evaluate the Effectiveness of Briviact (Brivaracetam) as Adjunctive Therapy in Patients With Epilepsy With Partial-onset Seizures in Daily Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Epilepsy; Partial epilepsies
- Focus Therapeutic Use
- Acronyms BASE
- Sponsors UCB; UCB Biopharma
- 06 Dec 2022 Results of post hoc analysis pooled from two Real-world Studies (EP0077 & EP0088) assessing Effectiveness and Tolerability of Brivaracetam by Number of Lifetime Antiseizure Medications in Adults with Focal Onset Seizures presented at the 76th Annual Meeting of the American Epilepsy Society
- 01 Sep 2021 Results evaluating retention and cognitive performance in patients aged 16years with focal seizures after 12 month adjunctive brivaracetam treatment, presented at the 34th International Epilepsy Congress
- 08 Dec 2020 Results of a third interim analysis presented at the 74th Annual Meeting of the American Epilepsy Society